Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Recipharm and LIDDS Form Mfg. Pact | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Recipharm and LIDDS Form Mfg. Pact

Establish industrial manufacturing capabilities for a novel prostate cancer product

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Recipharm and LIDDS have together set up a manufacturing line for LIDDS’ novel prostate cancer drug, Liproca Depot, at Recipharm in Solna, Sweden.

The manufacturing line is dedicated to the first product based on LIDDS’ NanoZolid technology. Clinical trial material has already been produced and the facility is ready for future commercial manufacturing of Liproca Depot or other pharmaceutical formulations based on the NanoZolid technology. The manufacturing line has been adapted for GMP production and is industrialized according to a unique process invented by LIDDS, involving the installation of novel equipment that is new to the pharmaceutical industry.

”We are proud of having reached this important milestone in the development of a new product allowing improved therapy for a serious disease,” said Torkel Gren, general manager of Recipharm’s facility in Solna. “This has been achieved by the hard work and close collaboration of experts at both LIDDS and Recipharm. LIDDS is a very innovative company and it has been extremely rewarding to work with the team.”

Monica Wallter, chief executive officer, LIDDS, said, “With the successful manufacturing performed at Recipharm, LIDDS can offer license agreements for Liproca Depot with the advantage of having validated production in place, saving both time and money for pharma companies. In addition, we now have an established manufacturing facility ready for other NanoZolid projects.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics